Latest European Web Survey on Drugs finds cannabis and ecstasy use most impacted by COVID-19

New survey results released today by the EU drugs agency (EMCDDA) reveal that cannabis and ecstasy use are the drug-consumption patterns most impacted by COVID-19 restrictions (1). The European Web Survey on Drugs found that, while herbal cannabis use increased, use of ‘party drug’ MDMA/ecstasy declined. The survey ran between March and April 2021 in 30 countries (21 EU and 9 non-EU) when many populations were under COVID-19-related lockdowns. 19.01.2022  European Web Survey on Drugs: Results